Ascensia Diabetes Care发起全球创新大赛

2017-09-18 佚名 MedSci原创

-寻求数字解决方案来解决2型糖尿病难题

葡萄牙里斯本2017年9月14日电 /美通社/ --  9月13日,在欧洲糖尿病研究协会(EASD)第53届年会期间,Ascensia Diabetes Care宣布发起Ascensia Diabetes Challenge。这项全球性的创新大赛,旨在寻求创新的数字解决方案来支持糖尿病管理并改善2型糖尿病患者的生活。大赛希望通过发掘创新的糖尿病解决方案,解决全球2型糖尿病的管理难题。决赛选手、亚军和冠军将获得总额高达200,000欧元的奖金,进一步支持他们的研发工作。

通过此次大赛,Ascensia希望支持那些正在研发改善2型糖尿病管理并有助于减轻个人、医疗系统和社会负担的数字解决方案的公司。尽管这个领域的解决方案和疗法每年都有所改善,但目前许多研发中的新技术需要更多投资,以便帮助2型糖尿病患者更好地自我管理生活的方方面面。

Ascensia Diabetes Care首席执行官Michael Kloss表示:“Ascensia很高兴推出这项大赛,我们想要鼓励糖尿病管理领域的创新,并重新考虑数字技术如何帮助2型糖尿病患者管理自己的日常生活。这项大赛代表新的方式来寻求我们自己研发工作以外的创新解决方案,从而帮助糖尿病患者。大赛不仅要解决糖尿病难题,也代表了开发新糖尿病解决方案方面的重要进展。大赛将寻找、支持和促进有望革新糖尿病管理的创业公司。我们希望这项大赛能够从无名小公司那里发现创新方案,我们想通过Ascensia的支持让他们帮助全球糖尿病患者。”

大赛将接受来自欧洲、美洲和亚太地区的报名,欧洲提交时间从2017年10月1日开始,亚太区和美洲的提交时间从2017年11月6日开始。请在线提交方案:ascensiadiabeteschallenge.com。

来自全球糖尿病和数字健康行业的独立专家以及Ascensia医疗、研发和商业团队的成员将担任评委,选出入围者和冠军。临床心理学家William Polonsky博士和专注于糖尿病与数字健康的全科医生Masood Nazir博士以及2型糖尿病博主Robin Swindell已经确定担任评委,其他评委名单将于稍后公布。

美国圣地亚哥Behavioral Diabetes Institute总裁兼创始人William Polonsky博士表示:“行为干预对于提高2型糖尿病自我管理十分重要,人们急需数字解决方案来帮助患者长期自我管理,并确保可持续的行为改善。可惜现有的数字解决方案还无法完全满足患者需求,也不能有效支持自我管理和长期行为改善。我很高兴加入Ascensia Diabetes Challenge,去发现创新方案来解决2型糖尿病带来的负担。”

2型糖尿病患者兼英国知名博主Robin Swindell表示:“与大部分2型糖尿病患者一样,我一年最多只花几小时来看专业医生。大部分时间,我们都靠自我管理。我们需要创新数字解决方案来更好地支持自我管理。创新解决方案需要个人化,契合患者的生活。创新方案还需提供定量数据,帮助患者更好地理解和管理病情并提供激励措施。数字解决方案能够满足这些需求。我很兴奋参与这项活动,并希望大赛能发现创新方案,为我和其他患者带来真正的改变。”

Ascensia与开放创新服务公司yet2携手发起了这项全球活动。yet2将负责管理方案提交流程和初步审核。他们将利用开放创新大赛方面的经验,推动方案提交审核流程、管理知识产权筛选并辅助评审过程。

Michael Kloss补充道:“作为一家专注于糖尿病的公司,我们希望推动糖尿病方案的创新发展,展示我们作为可靠合作伙伴对糖尿病患者的大力支持,并彰显我们对于继续研发新方案和寻求创新发展的决心。”

欲知Ascensia Diabetes Care详情,请查看:http://www.ascensia.com
欲知yet2详情,请查看:http://www.yet2.com

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901776, encodeId=f0da1901e76a7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Sep 28 06:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938751, encodeId=e4ec1938e512c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 09 17:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638043, encodeId=82f316380431a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 15 10:24:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760211, encodeId=c8d01e6021125, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 02 11:24:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285418, encodeId=ef831285418f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Sep 20 05:24:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901776, encodeId=f0da1901e76a7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Sep 28 06:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938751, encodeId=e4ec1938e512c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 09 17:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638043, encodeId=82f316380431a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 15 10:24:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760211, encodeId=c8d01e6021125, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 02 11:24:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285418, encodeId=ef831285418f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Sep 20 05:24:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
    2018-04-09 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901776, encodeId=f0da1901e76a7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Sep 28 06:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938751, encodeId=e4ec1938e512c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 09 17:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638043, encodeId=82f316380431a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 15 10:24:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760211, encodeId=c8d01e6021125, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 02 11:24:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285418, encodeId=ef831285418f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Sep 20 05:24:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901776, encodeId=f0da1901e76a7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Sep 28 06:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938751, encodeId=e4ec1938e512c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 09 17:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638043, encodeId=82f316380431a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 15 10:24:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760211, encodeId=c8d01e6021125, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 02 11:24:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285418, encodeId=ef831285418f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Sep 20 05:24:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1901776, encodeId=f0da1901e76a7, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Sep 28 06:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938751, encodeId=e4ec1938e512c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Apr 09 17:24:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638043, encodeId=82f316380431a, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Jun 15 10:24:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760211, encodeId=c8d01e6021125, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Sep 02 11:24:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285418, encodeId=ef831285418f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Wed Sep 20 05:24:00 CST 2017, time=2017-09-20, status=1, ipAttribution=)]